News | Myriad Genetics

New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations

Dec 11, 2020 | Pipeline | Products

Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression

Nov 17, 2020 | Products

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

Nov 16, 2020 | Pipeline | Products

New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis

Nov 11, 2020 | Pipeline | Products

Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter

Nov 09, 2020 | Financial

Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020

Nov 04, 2020 | Financial

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

Oct 16, 2020 | Pipeline | Products

Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

Oct 15, 2020 | Corporate

Myriad Genetics Expands Board of Directors with New Member

Sep 10, 2020 | Corporate

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

Aug 21, 2020 | Pipeline | Products

Myriad Genetics Announces Inducement Awards

Aug 14, 2020 | Corporate

Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors

Aug 13, 2020 | Corporate

Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results

Aug 13, 2020 | Financial

New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

Aug 10, 2020 | Pipeline | Products

Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

Aug 06, 2020 | Corporate | Financial

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

Jul 31, 2020 | Pipeline | Products

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

Jul 29, 2020 | Pipeline | Products

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

Jul 28, 2020 | Pipeline | Products

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

Jul 22, 2020 | Corporate

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

Jul 07, 2020 | Products | Pipeline

Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients

Jul 06, 2020 | Products

Myriad Launches New GeneSight® Psychotropic Patient Collection Kit

Jul 01, 2020 | Products | Pipeline

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

Jun 25, 2020 | Pipeline | Products

Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider

Jun 15, 2020 | Products | Pipeline

Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries

Jun 11, 2020 | Pipeline | Products

Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer

Jun 04, 2020 | Pipeline | Products

Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients

May 29, 2020 | Pipeline | Products

Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.

May 28, 2020 | Corporate

Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

May 26, 2020 | Pipeline | Products

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

May 20, 2020 | Pipeline | Products

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

May 11, 2020 | Pipeline | Products

Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results

May 05, 2020 | Financial

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

Apr 28, 2020 | Corporate | Financial

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder

Apr 20, 2020 | Pipeline | Products

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

Apr 08, 2020 | Financial

Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC

Apr 06, 2020 | Pipeline | Products

Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

Mar 30, 2020 | Products | Pipeline

Myriad Announces Board of Directors Leadership Transition

Mar 23, 2020 | Corporate

NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer

Mar 18, 2020 | Products

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

Feb 14, 2020 | Products | Pipeline

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

Feb 12, 2020 | Corporate

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

Feb 11, 2020 | Pipeline | Products

Myriad Announces Leadership Transition

Feb 06, 2020 | Corporate

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

Feb 06, 2020 | Financial

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

Jan 30, 2020 | Corporate | Financial

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

Jan 22, 2020 | Pipeline | Products

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

Jan 21, 2020 | Pipeline | Products

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations

Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis

Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter

Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

Myriad Genetics Expands Board of Directors with New Member

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

Myriad Genetics Announces Inducement Awards

Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors

Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results

New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients

Myriad Launches New GeneSight® Psychotropic Patient Collection Kit

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider

Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries

Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer

Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients

Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.

Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC

Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

Myriad Announces Board of Directors Leadership Transition

NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

Myriad Announces Leadership Transition

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference